Skip to main content
Erschienen in: Drugs & Therapy Perspectives 4/2024

Open Access 28.04.2024 | Correction

Correction to: Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA

verfasst von: Hannah A. Blair

Erschienen in: Drugs & Therapy Perspectives | Ausgabe 4/2024

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1007/​s40267-024-01055-y.
Correction to: Drugs (2024) 40:61–71 https://doi.org/10.1007/s40267-024-01055-y
The article “Buprenorphine extended‑release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA”, written by Hannah A. Blair, was originally published electronically in SpringerLink on 15 March 2024 without open access. After publication in volume 40, issue 2, pages 61–71, Braeburn Inc requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Braeburn Inc. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by-nc/​4.​0/​.
The original article has been corrected.
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by-nc/​4.​0/​.
download
DOWNLOAD
print
DRUCKEN

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de.

e.Med Innere Medizin

Kombi-Abonnement

Mit e.Med Innere Medizin erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Innere Medizin, den Premium-Inhalten der internistischen Fachzeitschriften, inklusive einer gedruckten internistischen Zeitschrift Ihrer Wahl.

e.Dent – Das Online-Abo der Zahnmedizin

Online-Abonnement

Mit e.Dent erhalten Sie Zugang zu allen zahnmedizinischen Fortbildungen und unseren zahnmedizinischen und ausgesuchten medizinischen Zeitschriften.

Metadaten
Titel
Correction to: Buprenorphine extended-release injection (Brixadi®) in the management of opioid use disorder: a profile of its use in the USA
verfasst von
Hannah A. Blair
Publikationsdatum
28.04.2024
Verlag
Springer International Publishing
Erschienen in
Drugs & Therapy Perspectives / Ausgabe 4/2024
Print ISSN: 1172-0360
Elektronische ISSN: 1179-1977
DOI
https://doi.org/10.1007/s40267-024-01066-9

Weitere Artikel der Ausgabe 4/2024

Drugs & Therapy Perspectives 4/2024 Zur Ausgabe